Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Stock Information for Exicure Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Exicure Inc.

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
Exicure, Inc. Reports Full Year 2024 Financial Results
Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.